spacer
The Healthcare Sales & Marketing Network celebrates 27 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  ganciclovir 

 HSMN NewsFeed - 29 Nov 2021
Viracta Therapeutics Announces Orphan Drug Designation Granted by FDA for its All-Oral Combination of Nanatinostat and Valganciclovir (Nana-val) for the Treatment of Epstein Barr Virus-Positive Diffuse Large B-cell Lymphoma
Biopharmaceuticals FDA
 HSMN NewsFeed - 6 Jul 2021
Viracta Therapeutics Announces the Appointment of Ayman El-Guindy, Ph.D., as Chief Scientific Officer and Key Additions to Management Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 8 Apr 2020
Viracta Receives Welcome FDA Guidance at Type C Meeting for the Treatment of EBV-Associated Lymphomas
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 16 Apr 2019
Viracta Receives Orphan Drug Designation from the US FDA for its Lead Epigenetic Drug Candidate Nanatinostat for EBV-Associated Cancers
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 3 Jun 2010
Bausch & Lomb Acquires Zirgan(R) (Ganciclovir Ophthalmic Gel 0.15%) From Sirion Therapeutics for the Treatment of Herpetic Keratitis
Biopharmaceuticals Ophthalmology Acquisitions
 HSMN NewsFeed - 16 Sep 2009
Sirion Therapeutics Announces FDA Approval of Zirgan(TM) (Ganciclovir Ophthalmic Gel) 0.15% for Herpetic Keratitis
Biopharmaceuticals Ophthalmology FDA
 HSMN NewsFeed - 31 Aug 2009
FDA Approves Valcyte(R) (valganciclovir hydrochloride) to Prevent Cytomegalovirus (CMV) Disease in Pediatric Patients Who Receive Heart or Kidney Transplants
Biopharmaceuticals FDA
 HSMN NewsFeed - 13 Feb 2009
IMPACT Study Demonstrates That Longer Prophylactic Therapy With Valcyte(R) (Valganciclovir Hydrochloride Tablets) Increases Protection Against CMV - the Most Serious Viral Infection Affecting Transplant Patients
Biopharmaceuticals
 HSMN NewsFeed - 13 Feb 2009
ViroPharma Announces Discontinuation of Maribavir Phase 3 Study in Liver Transplant Patients
Biopharmaceuticals
 HSMN NewsFeed - 26 Jan 2009
Sirion Therapeutics New Drug Application for Ganciclovir is Accepted for Review by the FDA for the Treatment of Ocular Herpes
Biopharmaceuticals Ophthalmology FDA
 HSMN NewsFeed - 30 Jun 2008
Tobira Therapeutics Inc. Announces Senior Management Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 24 Jun 2008
Sirion Therapeutics Announces FDA Approval of Durezol(TM) for Treatment of Postoperative Ocular Inflammation and Pain
Biopharmaceuticals Ophthalmology FDA
 HSMN NewsFeed - 25 Oct 2007
Sirion Therapeutics Announces Positive Phase III Results for Difluprednate
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 5 Jul 2007
ViroPharma Initiates Phase 3 Study of CAMVIA(TM) (maribavir) in Liver Transplant Patients
Biopharmaceuticals
 HSMN NewsFeed - 16 Apr 2007
Sirion Therapeutics Receives Orphan Drug Designation for Ophthalmic Drug to Treat Viral Eye Infection
Biopharmaceuticals Ophthalmology FDA
 HSMN NewsFeed - 9 Apr 2007
Sirion Therapeutics Completes $45 Million Series B Financing
Biopharmaceuticals Ophthalmology Venture Capital
 HSMN NewsFeed - 17 Jan 2007
Sirion Therapeutics Acquires U.S. License to Develop New Treatment for Viral Eye Infection
Biopharmaceuticals Ophthalmology Licensing
 HSMN NewsFeed - 18 Dec 2006
ZLB Behring Completes Purchase of CytoGam(R) Immunoglobulin Therapy From MedImmune
Biopharmaceuticals Acquisitions
Return to NewsFeed  

 Additional items found! 4

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 4 additional stories matching:
ganciclovir
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.